ArticleLeukemia2017
CD47 blockade enhances therapeutic activity of TCR mimic antibodies to ultra-low density cancer epitopes.
Article in Leukemia, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- CDH17-targeting CAR-NK cells synergize with CD47 blockade for potent suppression of gastrointestinal cancers.Acta pharmaceutica Sinica. B · 2025Article
- Optimizing CAR-T cell therapy for solid tumors: current challenges and potential strategies.Journal of hematology & oncology · 2024Review
- Facile repurposing of peptide-MHC-restricted antibodies for cancer immunotherapy.Nature biotechnology · 2023Article
- Potentiating antibody-dependent killing of cancers with CAR T cells secreting CD47-SIRPα checkpoint blocker.Blood · 2023Article
- Tumor-promoting myeloid cells in the pathogenesis of human oncoviruses: potential targets for immunotherapy.Cancer cell international · 2022Review
- The potential applications of T cell receptor (TCR)-like antibody in cervical cancer immunotherapy.Human vaccines & immunotherapeutics · 2021Review
- Development of a New Highly Selective Monoclonal Antibody against Preferentially Expressed Antigen in Melanoma (PRAME) and Identification of the Target Epitope by Bio-Layer Interferometry.International journal of molecular sciences · 2021Article
- Review
- Therapeutic modulation of the CD47-SIRPα axis in the pediatric tumor microenvironment: working up an appetite.Cancer drug resistance (Alhambra, Calif.) · 2020Review
- Cancer Testis Antigens and Immunotherapy: Where Do We Stand in the Targeting of PRAME?Cancers · 2019Review
- The Unique Mechanisms of Cellular Proliferation, Migration and Apoptosis are Regulated through Oocyte Maturational Development-A Complete Transcriptomic and Histochemical Study.International journal of molecular sciences · 2018Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.